Louis A. Peña, Ph.D. M.B.A.

 

Associate Professor of Practice
Director, Program in Life Sciences Innovation & Entrepreneurship

 

EDUCATION

• A.B. - Evolutionary Biology, Harvard, 1982
• Ph.D. - Cell Biology, UCLA, 1991
• Postdoc fellow - Molecular Neuroscience, Cold Spring Harbor, 1994
• Research fellow - Radiation Oncology, Sloan Kettering Cancer Ctr, 1998
• M.B.A. - Management, Stony Brook University, 2013

 

ACADEMIC & PROFESSIONAL POSITIONS

• 2023 - Associate Professor of Practice, Dept Biomedical Engineering, Stony Brook University, NY
• 2022 - 2023Scientific/Regulatory Consultant, Phoenix Tailings Inc, Woburn, MA
• 2009 - 2021Director, Nuclear and Radiochemistry Summer School, Brookhaven National Lab, Upton, NY
• 2016 - 2020Chief Scientific Officer & Managing Partner, METIS Laboratories Inc, Ronkonkoma, NY
• 2014 - 2016Director of Business Development, METIS Laboratories Inc, Valley Stream, NY
• 2012 - 2016Adjunct Associate Professor, Dowling College Townsend School of Business, Oakdale, NY
• 2012 - 2016Scientific/Business Consultant, Neworks Pre-Seed Bootcamp LLC, Stony Brook, NY
• 2008 - 2015Senior Scientist, Biosciences Dept, Brookhaven National Lab, Upton, NY
• 2005 - 2008Adjunct Assistant Professor, Dept Biomedical Engineering, Stony Brook University, NY
• 2004 - 2005Scientific Consultant, EISAI Inc, Andover MA
• 2004 - 2008Scientist, Medical Dept, Brookhaven National Lab, Upton, NY  
• 2002 - 2008Scientific Consultant, BioSurface Engineering Technologies Inc (BioSET), Rockville, MD  
• 2000 - 2008Faculty, Graduate Program in Neuroscience, Stony Brook University, NY           
• 2000 - 2004Associate Scientist, Medical Dept, Brookhaven National Lab, Upton, NY
• 1999 - 2000Assistant Scientist, Medical Dept, Brookhaven National Lab, Upton, NY

 

 

PUBLICATIONS

Click here for Louis A. Peña’s Google Scholar citations

 

 

PATENTS

• US # 7,414,028 - Growth factor analogs
• US # 7,528,105 - Heterodimeric chain synthetic heparin-binding growth factor analogs
• US # 7,700,563 - Synthetic heparin-binding growth factor analogs
• US # 8,101,570 - Single branch heparin-binding growth factor analogs
• US # 8,163,717 - Dual chain synthetic heparin-binding growth factor analogs
• US # 8,227,411 - FGF growth factor analogs
• US # 10,611,810 - Positive modulator of Bone Morphogenic Protein-2
• US # 11,078,244 - Composition and method for delivery of BMP-2 amplifier/co-activator for enhancement of osteogenesis

 

 

HONORS

• 1987: Excellence in Teaching, Charles R. Drew/UCLA Medical School
• 1998: Howard Temin Career Development Award, National Cancer Institute-NIH
• 2002, 2009: Outstanding Mentor Award, Office of Energy Education & Workforce Development, U.S. Department of Energy

 

 

COURSES TAUGHT

• BUS 510 - Technology Enterprises: Startups, Finance and Operations
• BME 511 - Technology Enterprises: Technology and Markets
• BME 670 - Special Topics in Biomedical Engineering (Technology Commercialization)

 

 

FUNDING AGENCIES

• U.S. Department of Energy
• NIH - National Cancer Institute
• NIH - National Institute of Allergy and Infectious Diseases
• NIH - National Institute of Neurological Disorders and Stroke
• National Science Foundation
• National Space Biomedical Research Institute
• BNL-CRADA
• BNL-LDRD
• Ford Foundation